Radar Telegram alerts Open Radar

Pharmaceutical company Eli Lilly has agreed to buy Calytrix Bio for up to $1.5 billion in cash, Reuters reports. The deal will allow the pharmaceutical giant to expand the development of drugs to treat rare blood diseases. The agreement stipulates an advance and graduated payments based on the results of clinical and regulatory trials.

תרגם לעברית

Кролик с Неглинной · · Source

Pharmaceutical company Eli Lilly has agreed to buy Calytrix Bio for up to $1.5 billion in cash, Reuters reports. The deal will allow the pharmaceutical giant to expand the development of drugs to treat rare blood diseases. The agreement stipulates an advance and graduated payments based on the results of clinical and regulatory trials.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram